---
title: "Why did Alnylam (ALNY) fall after its Q3 2026 beat? Demand lagged revenue"
canonical_url: https://www.stockexpertai.com/journal/2026-10-31/why-did-alnylam-alny-fall-after-its-q3-2026-beat-demand-lagged-revenue-a940746707a3
last_updated: 2026-10-31T05:43:47.170Z
section: "Biotech Brief"
author: "Stock Expert AI Research"
publisher: Stock Expert AI
tickers: ALNY
content_type: journal-article
---

# Why did Alnylam (ALNY) fall after its Q3 2026 beat? Demand lagged revenue

_Alnylam beat Q3 2026 revenue estimates, yet shares fell sharply after the Oct. 29 report, with news reports citing demand concerns; they closed at 165 USD on Oct. 30._

![Data cover: Why did Alnylam (ALNY) fall after its Q3 2026 beat? Demand lagged revenue](/public-objects/streetnews/2026-10-31/BIOTECH_BRIEF-cover-4d149a6e.jpg)
Stock Expert AI data cover: figures from Financial Modeling Prep; background is an illustrative public-domain photo, credited on the image.

Alnylam Pharmaceuticals (NASDAQ: ALNY) reported third-quarter revenue of $1.46B for the quarter ended Sept. 30, 2026, above the analyst estimate of $1.43B. The shares fell sharply after the Oct. 29 report, and news reports such as Zacks attributed the drop to concerns about demand growth. On Oct. 30, 2026, a day that also brought two analyst downgrades, the stock closed at 165 USD, down 5.17% that day. On the call, management said patient demand for the drug is growing more slowly than it hoped. The story here is a theme: when a new drug launch moves from the first rush of patients to a slower, harder phase, a good quarter can still disappoint. Figures are current as of Oct. 30, 2026 and cover the third quarter of fiscal 2026 unless noted.

## The theme: launches have two phases

A new drug often sells quickly at first because patients who have been waiting get treated right away. After that, growth depends on doctors changing habits, insurers approving coverage and clinics sorting out logistics. That phase is usually slower.

Alnylam's drug AMVUTTRA treats ATTR-CM, a heart condition caused by a misfolded protein. In its July statement, as quoted in a law-firm release, the company described "the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy." Investors are now asking how fast the steady phase can grow.

## Key facts

- **Revenue, Q3 FY2026 (ended Sept. 30, 2026):** $1.46B, up 16.7% from the year-ago quarter and above the $1.43B estimate.
- **Earnings per share reported Oct. 29, 2026:** 16.26 versus an estimate of 1.66. Net income was $2.17B, far above operating income of $345.8M. CFO Jeff Poulton said GAAP net income of $2.2 billion included a non-cash income tax benefit of approximately $1.9 billion from releasing the company's U.S. valuation allowance. That one-time item inflates net income and EPS, so operating income is the cleaner guide to the core business.
- **Stock move:** shares fell sharply after the Oct. 29 report. On Oct. 30, 2026 they closed at 165 USD, down 5.17% that day. The 52-week range is 163.3-479.79 USD.
- **Guidance:** management formally reiterated its 2026 guidance while saying it expects TTR product sales (the heart and nerve disease franchise) to land at the low end of the $4.2B-$4.5B range.
- **Market cap:** $22.08B.

| Metric | Q3 FY2026 | Q3 FY2025 (year-ago) |
|---|---|---|
| Revenue | $1.46B | $1.25B |
| Operating income | $345.8M | $368.0M |
| Operating margin | 23.7% | 29.5% |
| Gross margin | 75.2% | 84.2% |
| Free cash flow | $271.2M | $313.0M |

The table shows revenue rising while margins and free cash flow came in lower than a year earlier, but the year-ago quarter included a one-time $300 million Roche milestone. Management said that milestone primarily drove the 11% drop in non-GAAP operating income. Total revenue growth of 16.7% also compares with 52% growth in product revenue, because collaboration revenue fell with the Roche milestone. On the call, management said higher royalties to Sanofi primarily drove the decline in product gross margin.

## What happened

Alnylam reported on Oct. 29, 2026. Product revenue was $1.29B. According to the call, the AMVUTTRA ramp drove the growth, and TTR revenue outside the U.S. grew on uptake in Japan and Germany, partly offset by lower launch prices.

The tone on the call mattered more than the headline beat. CEO Yvonne Greenstreet said: "...we're not yet satisfied with the underlying demand growth we have observed." She also said that turning doctor interest into patient starts is taking longer than hoped. Newer prescribers have less experience with heart-muscle disease and more entrenched habits.

Chief Commercialization Officer Tolga Tanguler pointed to non-clinical hurdles: how clinics navigate the buy and bill, where patients are treated, and prior authorization. He said these ease as prescribers gain experience, and noted that only about a third of active prescribers have tried AMVUTTRA so far: "trial begets preference."

Part of the quarter's U.S. growth came from distributors holding more inventory, which does not reflect patient demand. Management said inventory and U.S. price will both weigh on reported growth in Q4 and that it does not expect demand growth to accelerate in Q4 2026.

A law firm also issued a release on Oct. 29, 2026 saying it is investigating possible securities claims after the earlier guidance cut in July. That release describes an investigation, not a filed lawsuit, and we have not verified any of its claims.

## Why it matters for investors

**The five-quarter trend.** Revenue was $1.25B, $1.10B, $1.17B, $1.29B and $1.46B from Q3 FY2025 through Q3 FY2026. Operating margin ran 29.5%, 12.0%, 23.0%, 17.9% and 23.7% over the same quarters. So Q3 improved on the two prior quarters but has not returned to the year-ago level. Gross margin slipped from 84.2% to 75.2% over the span.

**Cash flow.** Free cash flow (cash left after capital spending) was $313.0M in Q3 FY2025, then $140.3M, $48.7M and $40.6M, before reaching $271.2M in Q3 FY2026. The recent jump is large, but the prior two quarters were much lower, so one quarter does not yet make a trend.

**Balance sheet.** Cash and short-term investments were $3.59B against total debt of $1.26B at Sept. 30, 2026. That leaves the company with net cash. The Altman Z score (a bankruptcy-risk gauge) is 3.86, and the Piotroski score (a 0-9 financial health check) is 5.

**Valuation versus peers.** Alnylam's trailing price-to-earnings ratio is 8.10, but that is flattened by the one-time tax benefit in Q3 net income, so it is not a clean reading. Price-to-sales is 4.40 and price-to-free-cash-flow is 44.09. Its peers are not profitable: Arrowhead (ARWR, market cap $8.46B) has a net margin of -47.8%, and Ionis (IONS, market cap $7.23B) has -64.6%. Alnylam's trailing net margin is 54.3%, again lifted by the Q3 tax benefit. FMP's discounted-cash-flow model shows a value of -1457.73 USD per share, which is not a usable figure here.

**Analysts.** Of 52 ratings, 38 are buy, 13 are hold and 1 is sell, for a consensus of "Buy". The average price target is 330.54 USD (median 315.00 USD, range 225.00-455.00 USD), and the stock closed below even the lowest target. On Oct. 30, 2026, Raymond James cut its rating from Strong Buy to Outperform and Bernstein cut from Outperform to Market Perform, while Goldman Sachs, TD Cowen and RBC kept theirs.

**Our MoonshotScore.** Stock Expert AI's MoonshotScore V2 is 76.6, rated Strong. Growth (100) and quality (98) are the strongest pillars. Safety scores 67 and valuation 52. Momentum is the weak spot at 29, which fits the share price sitting near the bottom of its 52-week range.

## What could go wrong

- **Slower demand conversion.** Management said field-force investments are not yet turning into patient starts at the pace it expected.
- **A proposed federal rule.** CMS has proposed cutting Medicare Part B payments for drugs bought through the 340B discount program, effective Jan. 1, 2027, if finalized. Management expects a final rule soon, anticipates legal challenges from hospital groups, and said it could cause volatile Q4 orders.
- **Insurer policy.** UnitedHealth's Medicare Advantage plans adopted a more restrictive first-line AMVUTTRA policy effective Oct. 1. Existing patients should not be affected, but new patients could face delays.
- **Trial risk.** The company expanded its TRITON-CM study of nucresiran by 500 patients, to a total of 2,250, as a precaution against "the potential risk of lower than expected event rates." Management cited broader trends, including earlier diagnosis and greater use of background therapies such as SGLT2 inhibitors, that tend to reduce event rates and can compromise study power. It did not say the study has seen fewer events. Management said the underlying hypothesis is unchanged and expects a launch around 2030, subject to positive study results and regulatory approval.
- **Credibility.** This is the second time in a few months that the outlook has come under pressure. According to the law-firm release, the company lowered its full-year TTR guidance in July, and in October it said it expects the low end of the range.

## What to watch next

- **The final CMS 340B rule,** which management expects in the coming weeks.
- **Preliminary Q4 and full-year 2026 revenue,** which the company said it will share at the J.P. Morgan healthcare conference in January.
- **2027 product revenue guidance,** which management deferred to its full-year results in mid-February. FMP lists the next earnings date as Feb. 11, 2027, with an EPS estimate of 1.82 and a revenue estimate of $1.53B.
- **Whether new-prescriber activity turns into patient starts.** Management has reiterated confidence in total revenue growth of more than 25% a year through 2030, so demand data is the test of that claim.
- **Insider activity.** The recent filings we checked show no open-market insider purchases and 1 sale.

## Frequently asked questions

## Q: Why did Alnylam stock fall after beating earnings estimates?
Alnylam's shares fell sharply after the Oct. 29, 2026 report, and news reports such as Zacks attributed the drop to concerns about demand growth. Revenue beat estimates, but management said patient demand for AMVUTTRA grew more slowly than it wanted, that it expects 2026 TTR sales at the low end of its guided range, and that it does not expect demand to accelerate in Q4. The shares closed at 165 USD on Oct. 30, 2026, down 5.17% that day, when two firms also downgraded the stock.

## Q: Is Alnylam profitable?
Alnylam is profitable on an operating basis: operating income was $345.8M in the quarter ended Sept. 30, 2026. Net income of $2.17B was much larger because it included a non-cash income tax benefit of approximately $1.9 billion from releasing the U.S. valuation allowance, according to CFO Jeff Poulton. That one-time item inflates net income, so the operating figure is the cleaner guide to the core business. Its peers Arrowhead and Ionis are not profitable.

## Q: What do analysts expect for Alnylam stock now?
Analysts' consensus rating is "Buy", with 38 buy, 13 hold and 1 sell ratings. Their average price target is 330.54 USD and the range is 225.00-455.00 USD. Two firms lowered their ratings on Oct. 30, 2026. This is a report of analyst views, not a forecast or advice from us.

*Sources: Stock Expert AI market data and MoonshotScore, drawn from Financial Modeling Prep (FMP) figures as of Oct. 30, 2026. Management quotes come from the Oct. 29, 2026 earnings call transcript. The law-firm release and news headlines are third-party reports and were used only for context.*


*This is educational content, not investment advice. Past performance does not guarantee future results.*

## Related Tickers
- [ALNY](https://www.stockexpertai.com/stock/alny)

## Sources
- [Stock Expert AI ALNY page: quote, financials and MoonshotScore](https://www.stockexpertai.com/stock/alny)
- [globenewswire.com: Lost Money on Alnylam Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 28.31% Share Price Drop](https://www.globenewswire.com/news-release/2026/10/29/3391929/34548/en/lost-money-on-alnylam-pharmaceuticals-inc-stock-glancy-prongay-wolke-rotter-llp-continues-investigating-possible-securities-fraud-after-28-31-share-price-drop.html)
- [zacks.com: ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns](https://www.zacks.com/stock/news/3019865/alny-stock-down-25-despite-q3-earnings-beat-on-demand-growth-concerns?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-3019865)
- [seekingalpha.com: Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript](https://seekingalpha.com/article/4959365-alnylam-pharmaceuticals-inc-alny-q3-2026-earnings-call-transcript)
- [marketbeat.com: Alnylam Pharmaceuticals Q3 Earnings Call Highlights](https://www.marketbeat.com/instant-alerts/transcript-alnylam-pharmaceuticals-q3-earnings-call-highlights-2026-10-29/)
- [zacks.com: Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates](https://www.zacks.com/stock/news/3018671/alnylam-pharmaceuticals-alny-q3-earnings-and-revenues-top-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|yseop_template_4-3018671)

---
_Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article. Educational research, not financial advice._